2 stocks under 10 cents
Can there possibly be good buying in single-digit share prices? I’ve been trawling through the ASX-listed population looking for this kind of situation, and here are two single-digit share prices that I think fit the bill
Independent. Trusted. Proven.
Browse current and previous editions of Switzer Report
Can there possibly be good buying in single-digit share prices? I’ve been trawling through the ASX-listed population looking for this kind of situation, and here are two single-digit share prices that I think fit the bill
For the week ending Friday February 17 there were fifteen upgrades and seventeen downgrades for ASX-listed companies covered by brokers in the FNArena database.
Last year was dominated by persistent pessimism but this week showed that possibly over-the-top optimism is the investing theme for 2023.
Here are two companies with successful models for providing housing for downsizing retirees.
In our “HOT” stock column, Michael Gable, Managing Director of Fairmont Equities, says that the chart for Orica (ORI) is reflecting the potential for further upside.
There have been 11 upgrades and 8 downgrades from the 7 stockbrokers monitored by FNArena so far this week.
If I bought CBA shares this week, will I be eligible for the dividend, and how do I participate in the buy-back? Will CBA shares under the DRP be issued at a discount, and can I still change my participation? Is JB Hi-Fi a sell? What are the broker targets for Pilbara Minerals?
How you want to play investing from here could be determined this week, with the US set to see its latest CPI number for January.
I feel like a bit of a “broken record” when it comes to listed investment companies (LICs) premiums and discounts. I have never understood why an investor would pay $1.20 for something that is worth $1.00. This is what happens when investors choose to invest in listed investment companies trading at a premium to their NTA (net tangible asset value).
For our “HOT” stock, Raymond Chan, Head of Asian Desk at Morgans explains why he says to add Macquarie Bank (MQG) to your portfolio.
The fact of biotech investing is that the share prices are at the mercy of news flow from drug trial results, partnerships with bigger companies, regulatory interactions and a wide range of other events that can point to the increased – or decreased – likelihood of the drug, medical device or diagnostic test ever reaching the market.
For the week ending Friday the 10th there were eleven upgrades and twenty-two downgrades for ASX-listed companies covered by brokers in the FNArena database.
We’re in the hands of central banks right now.
Retail investors can cut through the complexity of options-market by using ETFs and active funds.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.